trans-sodium-crocetinate and Rhabdomyosarcoma

trans-sodium-crocetinate has been researched along with Rhabdomyosarcoma* in 1 studies

Other Studies

1 other study(ies) available for trans-sodium-crocetinate and Rhabdomyosarcoma

ArticleYear
In vitro studies on the selective cytotoxic effect of crocetin and quercetin.
    Fitoterapia, 2000, Volume: 71, Issue:4

    Crocetin (5-20 microg/ml), quercetin (10-40 microg/ml), and cisplatin (60-180 microg/ml) used as a positive control drug, were tested against human rhabdomyosarcoma (RD) cells and African green monkey kidney (Vero) cells. The cell viability, morphological changes, and lactate dehydrogenase activity were assessed. RD cell growth was found to be inhibited dose dependently by the three tested compounds. Morphological observation by phase contrast microscopy revealed that both crocetin and quercetin caused intense damage only on the malignant (RD) cells, whereas mild toxic effect was seen with cisplatin also on normal (Vero) cells.

    Topics: Animals; Anticarcinogenic Agents; Carotenoids; Chlorocebus aethiops; Cisplatin; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Quercetin; Rhabdomyosarcoma; Tumor Cells, Cultured; Vitamin A

2000